FRANKFURT, Nov 6 (Reuters) - Colorectal cancer drug Erbitux failed to improve survival compared to a standard treatment in a late-stage trial, German drugmaker Merck (MRCG.DE: Quote, Profile, Research) and U.S. firm Bristol-Myers Squibb (BMY.N: Quote, Profile, Research) said on Monday.
